newsfilter
← Latest News
GlobeNewswire·

INVO Fertility Announces Five Poster Presentations Highlighting Platelet-Rich Plasma Research at the 2026 Midwest Reproductive Symposium International

  • INVO Fertility, Inc. announced that Dr. Gretchen Collins from its Wisconsin Fertility Institute presented five poster abstracts at the 2026 Midwest Reproductive Symposium (MRSi) held in Chicago from July 26-29, 2026.
  • The studies evaluated ovarian & subendometrial platelet-rich plasma (PRP) therapies for patients with prior poor IVF outcomes, diminished ovarian response, thin endometrial lining, or other limiting factors.
  • CEO Steve Shum highlighted the presentations as evidence of clinical expertise & patient-centered innovation following the introduction of PRP therapy in Wisconsin the previous year.
  • COO April McGhee stated that supporting physician-led research contributes to better patient care & advances the company's mission to expand access to assisted reproductive technology.
  • Key findings on age & ovarian reserve showed patients under 35 had robust improvements in oocyte yield & embryo development, while those aged 40+ showed limited responses & high aneuploidy rates.
  • A study on patients with prior poor outcomes reported increased high-quality blastocyst development, with two patients moving from no euploid embryos to multiple, & two achieving spontaneous conception.
  • Research on poor responders indicated PRP converted previously cancelled cycles into viable retrievals, with increased antral follicle counts, oocyte yields, & mature oocyte counts in a subset of patients.
  • Subendometrial PRP administered at hysteroscopy improved embryo transfer feasibility for 7 of 9 patients with poor endometrial development, resulting in two ongoing pregnancies & one miscarriage.
  • Another study on thin endometrial lining showed thickness improved from 6.1 mm to 8.1 mm in 8 of 9 patients, with restoration of a trilaminar pattern & resolution of intrauterine fluid.
  • The company emphasized that all five retrospective cohort studies warrant confirmation in larger, prospective investigations.
  • INVO Fertility operates four U.S. fertility clinics & sells its proprietary INVOcell device, which enables intravaginal culture (IVC) for fertilization & early embryo development within the woman's body.